statistiche ricercatore

Nazione	#
IT - Italia	12.337
US - Stati Uniti d'America	1.123
SG - Singapore	225
CN - Cina	126
BR - Brasile	77
VN - Vietnam	67
SE - Svezia	66
FI - Finlandia	28
DE - Germania	23
FR - Francia	23
CA - Canada	14
HK - Hong Kong	14
IN - India	13
BD - Bangladesh	11
GB - Regno Unito	11
ZA - Sudafrica	9
AR - Argentina	8
NL - Olanda	7
KR - Corea	6
MX - Messico	6
UA - Ucraina	6
AT - Austria	5
IQ - Iraq	5
TR - Turchia	5
UZ - Uzbekistan	5
BE - Belgio	4
JP - Giappone	4
MY - Malesia	4
AE - Emirati Arabi Uniti	3
ES - Italia	3
IE - Irlanda	3
PK - Pakistan	3
PL - Polonia	3
SA - Arabia Saudita	3
BO - Bolivia	2
CL - Cile	2
CO - Colombia	2
CZ - Repubblica Ceca	2
GR - Grecia	2
HU - Ungheria	2
ID - Indonesia	2
KZ - Kazakistan	2
LT - Lituania	2
PE - Perù	2
PH - Filippine	2
RU - Federazione Russa	2
UY - Uruguay	2
AD - Andorra	1
AL - Albania	1
AU - Australia	1
CR - Costa Rica	1
EC - Ecuador	1
ET - Etiopia	1
GT - Guatemala	1
IL - Israele	1
IR - Iran	1
JO - Giordania	1
KE - Kenya	1
KG - Kirghizistan	1
KH - Cambogia	1
LA - Repubblica Popolare Democratica del Laos	1
LB - Libano	1
MD - Moldavia	1
NZ - Nuova Zelanda	1
OM - Oman	1
PS - Palestinian Territory	1
PT - Portogallo	1
PY - Paraguay	1
RO - Romania	1
ZW - Zimbabwe	1
Totale	14.299

Nome	#
Performance in daily activities, cognitive impairment and perception in multiple sclerosis patients and their caregivers	3.670
Cognition in multiple sclerosis: Between cognitive reserve and brain volume	2.877
Does focal inflammation have an impact on cognition in multiple sclerosis? An MRI study	2.105
Effects of Pregnancy and Breastfeeding on Clinical Outcomes and MRI Measurements of Women with Multiple Sclerosis: An Exploratory Real-World Cohort Study	1.035
Leukocyte telomere length in women with multiple sclerosis: Comparison with healthy women during pregnancy and puerperium	741
An overview of the efficacy and safety of ozanimod for the treatment of relapsing multiple sclerosis	594
What happens after fingolimod discontinuation? A multicentre real-life experience	574
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies	563
Brain Volume and Perception of Cognitive Impairment in People With Multiple Sclerosis and Their Caregivers	495
Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients	481
Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up study	479
The Dimethyl Fumarate Experience: A Handy Drug With Broad Clinical Utility	453
Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccination	280
Totale	14.347

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	891	59	29	47	62	38	26	34	53	114	117	168	144
2022/2023	1.628	100	243	247	129	123	223	92	109	88	85	108	81
2023/2024	1.677	167	86	60	96	143	272	221	146	80	125	145	136
2024/2025	3.494	697	891	352	347	197	191	287	19	49	53	339	72
2025/2026	1.307	103	59	117	120	105	97	289	100	66	120	72	59
2026/2027	11	11	0	0	0	0	0	0	0	0	0	0	0
Totale													14.347

UNICA IRIS Institutional Research Information System